{"id":6323,"date":"2019-12-17T18:51:12","date_gmt":"2019-12-17T18:51:12","guid":{"rendered":"https:\/\/www.lymphoma.ca\/cll-sll-patient-survey-2\/"},"modified":"2020-04-14T21:19:43","modified_gmt":"2020-04-14T21:19:43","slug":"cll-sll-patient-survey-2","status":"publish","type":"post","link":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/","title":{"rendered":"CLL\/SLL Patient Survey"},"content":{"rendered":"

If you have CLL or SLL and have been treated with the following therapies, you can help by completing our survey:<\/h4>\n
    \n
  1. Venetoclax (Venclexta) + obinutuzumab (Gazyva) for first-line treatment of CLL\/SLL<\/a><\/strong><\/li>\n
  2. Acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for first-line treatment of CLL\/SLL<\/a><\/strong><\/li>\n
  3. Acalabrutinib (Calquence) monotherapy for treatment of relapsed\/refractory CLL\/SLL<\/strong><\/a><\/li>\n<\/ol>\n

    Lymphoma Canada and CLL Patient Advocacy Group (CLLPAG) are preparing submissions for the pan­Canadian Oncology Drug Review (pCODR)<\/a> so that CLL\/SLL patients in Canada can gain access to these therapies.<\/p>\n

    The survey<\/a> results will provide us with the patient input required for the submissions. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.<\/p>\n

    You do not<\/span> <\/strong>need to live in Canada to complete this survey.<\/p>\n

    BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THESE NEW TREATMENTS IN CANADA.<\/h4>\n

    The survey will be open until midnight Pacific Time on Friday, February 7th<\/sup>, 2020<\/strong> and should only take 10 minutes of your time.<\/p>\n

    You may access the survey by clicking the link below.<\/p>\n

    Survey for CLL\/SLL Patients: Experience with New Therapies<\/a><\/p>\n

     <\/p>\n","protected":false},"excerpt":{"rendered":"

    If you have CLL or SLL and have been treated with the following therapies, you can help by completing our survey: Venetoclax (Venclexta) + obinutuzumab (Gazyva) for first-line treatment of…<\/p>\n","protected":false},"author":1,"featured_media":2171,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":{"0":"post-6323","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-nouvelles"},"acf":[],"yoast_head":"\nCLL\/SLL Patient Survey - Lymphoma Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CLL\/SLL Patient Survey - Lymphoma Canada\" \/>\n<meta property=\"og:description\" content=\"If you have CLL or SLL and have been treated with the following therapies, you can help by completing our survey: Venetoclax (Venclexta) + obinutuzumab (Gazyva) for first-line treatment of...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Lymphoma Canada\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LymphomaCanada\" \/>\n<meta property=\"article:published_time\" content=\"2019-12-17T18:51:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-14T21:19:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2014\/07\/survey.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"720\" \/>\n\t<meta property=\"og:image:height\" content=\"540\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:site\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4\"},\"headline\":\"CLL\/SLL Patient Survey\",\"datePublished\":\"2019-12-17T18:51:12+00:00\",\"dateModified\":\"2020-04-14T21:19:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/\"},\"wordCount\":207,\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2014\/07\/survey.gif\",\"articleSection\":[\"Nouvelles\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/\",\"name\":\"CLL\/SLL Patient Survey - Lymphoma Canada\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2014\/07\/survey.gif\",\"datePublished\":\"2019-12-17T18:51:12+00:00\",\"dateModified\":\"2020-04-14T21:19:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#primaryimage\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2014\/07\/survey.gif\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2014\/07\/survey.gif\",\"width\":720,\"height\":540},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.lymphoma.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CLL\/SLL Patient Survey\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"name\":\"Lymphoma Canada\",\"description\":\"Information. Help. Hope.\",\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\",\"name\":\"Lymphoma Canada\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"width\":343,\"height\":343,\"caption\":\"Lymphoma Canada\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LymphomaCanada\",\"https:\/\/x.com\/lymphomacanada\",\"https:\/\/www.linkedin.com\/company\/lymphoma-canada\/\",\"http:\/\/instagram.com\/lymphomacanada\",\"http:\/\/www.youtube.com\/user\/LymphomaTV\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/www.lymphoma.ca\/fr\/author\/erezz_oxmaxp0p\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CLL\/SLL Patient Survey - Lymphoma Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/","og_locale":"fr_FR","og_type":"article","og_title":"CLL\/SLL Patient Survey - Lymphoma Canada","og_description":"If you have CLL or SLL and have been treated with the following therapies, you can help by completing our survey: Venetoclax (Venclexta) + obinutuzumab (Gazyva) for first-line treatment of...","og_url":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/","og_site_name":"Lymphoma Canada","article_publisher":"https:\/\/www.facebook.com\/LymphomaCanada","article_published_time":"2019-12-17T18:51:12+00:00","article_modified_time":"2020-04-14T21:19:43+00:00","og_image":[{"width":720,"height":540,"url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2014\/07\/survey.gif","type":"image\/gif"}],"author":"admin","twitter_card":"summary_large_image","twitter_creator":"@lymphomacanada","twitter_site":"@lymphomacanada","twitter_misc":{"\u00c9crit par":"admin","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#article","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/"},"author":{"name":"admin","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4"},"headline":"CLL\/SLL Patient Survey","datePublished":"2019-12-17T18:51:12+00:00","dateModified":"2020-04-14T21:19:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/"},"wordCount":207,"publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2014\/07\/survey.gif","articleSection":["Nouvelles"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/","url":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/","name":"CLL\/SLL Patient Survey - Lymphoma Canada","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#primaryimage"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2014\/07\/survey.gif","datePublished":"2019-12-17T18:51:12+00:00","dateModified":"2020-04-14T21:19:43+00:00","breadcrumb":{"@id":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#primaryimage","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2014\/07\/survey.gif","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2014\/07\/survey.gif","width":720,"height":540},{"@type":"BreadcrumbList","@id":"https:\/\/www.lymphoma.ca\/fr\/cll-sll-patient-survey-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lymphoma.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"CLL\/SLL Patient Survey"}]},{"@type":"WebSite","@id":"https:\/\/www.lymphoma.ca\/fr\/#website","url":"https:\/\/www.lymphoma.ca\/fr\/","name":"Lymphoma Canada","description":"Information. Help. Hope.","publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.lymphoma.ca\/fr\/#organization","name":"Lymphoma Canada","url":"https:\/\/www.lymphoma.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","width":343,"height":343,"caption":"Lymphoma Canada"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LymphomaCanada","https:\/\/x.com\/lymphomacanada","https:\/\/www.linkedin.com\/company\/lymphoma-canada\/","http:\/\/instagram.com\/lymphomacanada","http:\/\/www.youtube.com\/user\/LymphomaTV"]},{"@type":"Person","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4","name":"admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/www.lymphoma.ca\/fr\/author\/erezz_oxmaxp0p\/"}]}},"_links":{"self":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/6323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/comments?post=6323"}],"version-history":[{"count":1,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/6323\/revisions"}],"predecessor-version":[{"id":6324,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/6323\/revisions\/6324"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media\/2171"}],"wp:attachment":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media?parent=6323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/categories?post=6323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/tags?post=6323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}